Boehringer Ingelheim: Breast Neoplasms trials
The registry lists 16 Breast Neoplasms studies with Boehringer Ingelheim as lead sponsor. 1 are open to participants now and 12 have results posted.
Phase 1 6Phase 2 9Phase 3 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingNCT06324357Phase 1/2
- The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has SpreadCompletedNCT03659136Phase 2Results posted
- This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast CancerCompletedNCT03099174Phase 1Results posted
- Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.CompletedNCT01649271Phase 1Results posted
- Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain MetastasesCompletedNCT01441596Phase 2Results posted
- Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast CancerCompletedNCT01325428Phase 2Results posted
- LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment FailuresCompletedNCT01271725Phase 2Results posted
- LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin TreatmentCompletedNCT01125566Phase 3Results posted
- Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.CompletedNCT00950742Phase 1Results posted
- 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or TrastuzumabCompletedNCT00826267Phase 2Results posted
- BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast CancerCompletedNCT00708214Phase 2Results posted
- Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab TherapyCompletedNCT00431067Phase 2Results posted
- An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast CancerCompletedNCT00425854Phase 2Results posted
- Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United StatesActive, not recruitingNCT07342309
- Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast CancerTerminatedNCT02254031Phase 1
- Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast CancerCompletedNCT02254005Phase 1